pI: 8.8461 |
Length (AA): 822 |
MW (Da): 90554 |
Paralog Number:
0
Signal peptide: Y | GPI Anchor: N | Predicted trans-membrane segments: 9
Targets have been classified into druggability groups (DG) according to their druggability score in network driven prioritizations. DGs range from 1 to 5; the higher the group number, the higher the chance of the target to be druggable
Modbase 3D models:
PDB Structures:
Upregulation Percent | Ranking | Stage | Dataset |
---|---|---|---|
Lower 20-40% percentile | amastigotes. | Fernandes MC |
Upregulation Percent | Ranking | Stage | Dataset |
---|---|---|---|
Lower 0-20% percentile | metacyclic. | Fernandes MC |
Fernandes MC | Dual Transcriptome Profiling of Leishmania-Infected Human Macrophages Reveals Distinct Reprogramming Signatures. |
Ortholog group members (OG5_129144)
Species | Accession | Gene Product |
---|---|---|
Arabidopsis thaliana | AT1G16900 | Dol-P-Man:Man(6)GlcNAc(2)-PP-Dol alpha-1,2-mannosyltransferase |
Brugia malayi | Bm1_09555 | Plasmid Maintenance Protein containing protein |
Candida albicans | CaO19.11922 | similar to S. cerevisiae endoplasmic reticulum mannosyltranferase |
Candida albicans | CaO19.4442 | similar to S. cerevisiae endoplasmic reticulum mannosyltranferase |
Caenorhabditis elegans | CELE_C14A4.3 | Protein C14A4.3 |
Dictyostelium discoideum | DDB_G0279349 | dolichyl-phosphate-mannose alpha-1,2-mannosyltransferase |
Drosophila melanogaster | Dmel_CG11851 | CG11851 gene product from transcript CG11851-RA |
Echinococcus granulosus | EgrG_000455200 | glycosyltransferase |
Echinococcus multilocularis | EmuJ_000455200 | glycosyltransferase |
Homo sapiens | ENSG00000086848 | ALG9, alpha-1,2-mannosyltransferase |
Leishmania donovani | LdBPK_120145.1 | dolichyl-P-Man:GDP-Man5GlcNAc2-PP-dolichyl alpha-1,2-mannosyltransferase, putative |
Leishmania infantum | LinJ.12.0140 | Alg9-like mannosyltransferase, putative |
Leishmania major | LmjF.12.0160 | dolichyl-P-Man:GDP-Man5GlcNAc2-PP-dolichyl alpha-1,2-mannosyltransferase, putative |
Leishmania mexicana | LmxM.12.0160 | hypothetical protein, conserved |
Loa Loa (eye worm) | LOAG_00676 | plasmid Maintenance protein containing protein |
Mus musculus | ENSMUSG00000032059 | asparagine-linked glycosylation 9 (alpha 1,2 mannosyltransferase) |
Oryza sativa | 4325533 | Os01g0209000 |
Onchocerca volvulus | OVOC10426 | Putative glycosyltransferase |
Saccharomyces cerevisiae | YNL219C | dolichyl-P-Man:Man(6)GlcNAc(2)-PP-dolichol alpha-1,2-mannosyltransferase |
Schistosoma japonicum | Sjp_0106360 | ko:K03846 alpha-1,2-mannosyltransferase, putative |
Schistosoma mansoni | Smp_103930.6 | glycosyltransferase |
Schistosoma mansoni | Smp_103930.2 | glycosyltransferase |
Schistosoma mansoni | Smp_103930.5 | glycosyltransferase |
Schmidtea mediterranea | mk4.001456.05 | Glycosyltransferase, putative |
Trypanosoma brucei gambiense | Tbg972.6.840 | Alg9-like mannosyltransferase, putative |
Trypanosoma brucei | Tb927.6.1140 | dolichyl-P-Man:GDP-Man5GlcNAc2-PP-dolichyl alpha-1,2-mannosyltransferase, putative |
Trypanosoma cruzi | TcCLB.509429.220 | dolichyl-P-Man:GDP-Man5GlcNAc2-PP-dolichyl alpha-1,2-mannosyltransferase, putative |
Trypanosoma cruzi | TcCLB.507603.150 | dolichyl-P-Man:GDP-Man5GlcNAc2-PP-dolichyl alpha-1,2-mannosyltransferase, putative |
Gene/Ortholog | Organism | Phenotype | Source Study |
---|---|---|---|
Tb927.6.1140 | Trypanosoma brucei | no significant loss or gain of fitness in bloodstream forms (3 days) | alsford |
Tb927.6.1140 | Trypanosoma brucei | no significant loss or gain of fitness in bloodstream forms (6 days) | alsford |
Tb927.6.1140 | Trypanosoma brucei | no significant loss or gain of fitness in procyclic forms | alsford |
Tb927.6.1140 | Trypanosoma brucei | significant gain of fitness in differentiation of procyclic to bloodstream forms | alsford |
keio | Systematic single-gene knock-out mutants of E. coli K12 | The Keio Collection |
wormbase | C. elegans RNAi experiments | WormBase web site, http://www.wormbase.org, release WS170 |
alsford | High-throughput phenotyping using parallel sequencing of RNA interference targets in the African trypanosome | Genome Res 2011, 21:915-924 |
yeastgenome | Systematic deletion of yeast genes | Saccharomyces Genome Database |
nmpdr | Genome-scale essentiality datasets from published studies (M. tuberculosis) | National Microbial Pathogen Data Resource |
blattner | Systematic mutagenesis of the E. coli (MG1655) genome | J Bacteriol 2004, 186:4921-4930 |
shigen | Profiling of E. coli Chromosome (PEC) | National Institute of Genetics, Japan |
neb | C. elegans RNAi phenotypes | Data obtained from Wormbase WS150, curated by K. Chaudary and T. Carlow, New England Biolabs |
gerdes | Experimental determination and system-level analysis of essential genes in E. coli MG1655 | Gerdes et al., J Bacteriol. 2003 185:5673-84 |
In TDR Targets, information about phenotypes that are caused by drugs, or by genetic manipulation of cells (e.g. gene knockouts or knockdowns) is manually curated from the literature. These descriptions help to describe the potential of the target for drug development. If no information is available for this gene or if the information is incomplete, this may mean that i) the papers containing this information either appeared after the curation effort for this organism was carried out or they were inadvertently missed by curators; or that ii) the curation effort for this organism has not yet started.
In any case, if you have information about papers containing relevant validation data for this target, please contact us.
Druggability index (range: 0 to 1): 0.1